scispace - formally typeset
E

Esa R. Korpi

Researcher at University of Helsinki

Publications -  176
Citations -  6512

Esa R. Korpi is an academic researcher from University of Helsinki. The author has contributed to research in topics: GABAA receptor & Receptor. The author has an hindex of 44, co-authored 171 publications receiving 6112 citations. Previous affiliations of Esa R. Korpi include University of Turku & Uppsala University.

Papers
More filters
Journal ArticleDOI

Regulation of GABA(A) receptor subunit expression by pharmacological agents.

TL;DR: Drug development for neuropsychiatric disorders, including epilepsy, alcoholism, schizophrenia, and anxiety, has been ongoing for several years and one key step to extend drug development related to GABAA receptors is likely to require deeper understanding of the adaptational mechanisms of neurons, receptors themselves with interacting proteins, and finally receptor subunits during drug action and in neuropsychiatrics disease processes.
Journal Article

Selective antagonist for the cerebellar granule cell-specific gamma-aminobutyric acid type A receptor.

TL;DR: Furosemide is the first subtype-selective GABAA receptor (alpha 6 beta 2/3 gamma 2) antagonist and should facilitate studies on cerebellar physiology and might serve as a prototypic structure for the development of additional sub type- selective GabAA ligands.
Journal ArticleDOI

Modifying the Subunit Composition of TASK Channels Alters the Modulation of a Leak Conductance in Cerebellar Granule Neurons

TL;DR: It is demonstrated that TASK-1 channels contribute to the properties of IK(SO) in adult CGNs, however, TAS k2P channel subunit composition does not alter the resting excitability of C GNs but does influence sensitivity to endogenous modulators such as Zn2+ and H+.
Journal ArticleDOI

GABA(A) receptor subtypes as targets for neuropsychiatric drug development.

TL;DR: The greatest advances have occurred in the clarification of the molecular and behavioral mechanisms of action of the GABA(A) receptor agonists already in the clinical use, such as benzodiazepines and anesthetics, rather than in the introduction of novel compounds to clinical practice.